A Phase 1 interventional study of Marketed paracetamol and Experimental paracetamol formulation in Healthy Subjects, sponsored by GlaxoSmithKline. Withdrawn at 2 sites in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-06.
Sponsored by GlaxoSmithKline · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single dose pharmacoscintigraphic study investigating the differences in paracetamol absorption between two formulations.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Marketed formulation
Drug: Marketed paracetamol
Experimental formulation
Drug: Experimental paracetamol formulation
marketed formulation
Experimental formulation
Time of onset and completion of disintegration based on release of radiolabeled markers in a fed condition
Time frame: Baseline to 12 hours post dosing
To assess the gastrointestinal transit by qualitative scintigraphic analysis
Time frame: Baseline to 12 hours post dosing
The record gives a start of Apr 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen